New drug duo aims to shrink throat cancer before standard therapy
NCT ID NCT07267338
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 26 times
Summary
This study tests whether giving two drugs—pembrolizumab and MRG-003—before standard chemoradiation can improve outcomes for people with advanced nasopharyngeal cancer linked to the Epstein-Barr virus. About 35 adults with stage III-IVa disease will receive the combination, then standard treatment, followed by more pembrolizumab. The goal is to see how many patients have a complete response before starting standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NPC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Xiehe Hospital
Wuhan, Hubei, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.